Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase

Journal of Clinical Pharmacology

Volumn 47, Issue 10, 2007, Pages 1277-1282

  Van Giersbergen, Paul L M ^a   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Food effect; Gender effect; Healthy subjects; Miglustat; Pharmacokinetics

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; MIGLUSTAT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; NORMAL HUMAN; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

1-DEOXYNOJIRIMYCIN; ADOLESCENT; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; GLUCOSYLTRANSFERASES; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 34648822560     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007305298     Document Type: Article

References (21)

1. Beutler B., Grabowski GA Glucocerebroside lipidoses: Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill ; 1995.
2. Cox T., Schofield JP Gaucher's disease: clinical features and natural history. Bailliere's Clin Haematol. 1997 ; 10: 657-689.
3. Zimran A., Kay A., Gelbart T., et al. Gaucher disease: clinical, laboratory, radiologic, and genetic features. Medicine (Baltimore). 1992 ; 71: 337-353.
4. Inokuchi J., Radin NS Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol inhibitor of murine glucocerebroside synthetase. J Lipid Chem. 1987 ; 28: 565-571.
5. Platt FM, Neises GR, Dwek RA, Butters TD N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 1994 ; 269: 8362-8365.
6. Cox T., Lachmann R., Hollak C., et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000 ; 355: 1481-1485.
7. Heitner R., Elstein D., Aerts J., van Weely S., Zimran A. Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis. 2002 ; 28: 127-133.
8. Fischer PB, Collin M., Karlsson GB, et al. The α-glucosidase inhibitor N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J Virol. 1995 ; 69: 5791-5797.
9. Tierney M., Pottage J., Kessler H., et al. The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). J Acquir Immun Defic Syndr Hum Retrovirol. 1995 ; 10: 549-553.
10. Welling PG Effects of food on drug absorption. Annu Rev Nutr. 1996 ; 16: 383-415.
11. Singh BN Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999 ; 37: 213-255.
12. Gibaldi M., Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982.
13. Fleisher D., Li C., Zhou Y., Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. Clin Pharmacokinet. 1999 ; 36: 233-254.
14. Andersson U., Butters TD, Dwek RA, Platt FM N- butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vivo and in vitro. Biochem Pharmacol. 2000 ; 59: 821-829.
15. Pastores GM, Barnett NL Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opin Investig Drugs. 2003 ; 12: 273-281.
16. Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet. 2002 ; 41: 329-342.
17. Sica DA, Wood M., Hess M. Gender and its effect in cardiovascular pharmacotherapeutics: recent considerations. Congestive Heart Failure. 2005 ; 11: 163-166.
18. Gandhi M., Aweeka F., Greenblatt RM, Blaschke TF Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004 ; 44: 499-523.
19. Pleym H., Spigset O., Kharasch ED, Dale O. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand. 2003 ; 47: 241-259.
20. Hutson WR, Roehrkasse RL, Wald A. Influence of gender and menopause on gastric emptying and motility. Gastroenterology. 1989 ; 96: 11-17.
21. Sadik R., Abrahamsson H., Stotzer PO Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol. 2003 ; 38: 36-42.